News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novel Antiplatelet May Boost Coronary Artery Bypass Graft Survival, Uppsala University Hospital Study


12/30/2010 7:11:20 AM

MedPageToday -- The novel reversible antiplatelet agent ticagrelor (Brilinta) was associated with lower mortality from coronary artery bypass graft surgery (CABG) compared with standard clopidogrel (Plavix), according to a subanalysis of the pivotal PLATO trial.

Read at MedPageToday


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES